IL1 signalling in relation to inflammation in cancer has been extensively studied and consequently, IL1B blockers and the receptor antagonist IL1RA are of clinical interest (Homey et al., 2002; Chittezhath et al., 2014; Balkwill and Mantovani, 2001; Kaplanov et al., 2019; Lappano et al., 2020). Here, IL1B is linked to cancer.